Press Releases from Leaders in Pharmaceutical Business Intelligence (LPBI): FIVE new e-Book in our BioMed e-Series are NOW available for Kindle on Amazon.com

« Will President Obama’ s Cancer Immunotherapy Colloquium (dubbed Moonshot) mean Government is Fully Behind the War on Cancer or have we heard this before?

JP Morgan Healthcare Conference: Highlights for Day Three and Day Four »

Press Releases from Leaders in Pharmaceutical Business Intelligence (LPBI): FIVE new e-Book in our BioMed e-Series are NOW available for Kindle on Amazon.com

January 19, 2016 by 2012pharmaceutical

Press Releases from Leaders in Pharmaceutical Business Intelligence (LPBI): FIVE new e-Book in our BioMed e-Series are NOW available for Kindle on Amazon.com

Editor-in-Chief, BioMED e-Series: Aviva Lev-Ari, PhD, RN

2016 WE ARE ON AMAZON.COM

http://www.amazon.com/dp/B00DINFFYC

http://www.amazon.com/dp/B018Q5MCN8

http://www.amazon.com/dp/B018PNHJ84

http://www.amazon.com/dp/B018DHBUO6

http://www.amazon.com/dp/B013RVYR2K

http://www.amazon.com/dp/B012BB0ZF0

http://www.amazon.com/dp/B019UM909A

http://www.amazon.com/dp/B019VH97LU

Leaders in Pharmaceutical Business Intelligence (LPBI) would like to announce the First volume of their BioMedical E-Book Series B: Series B: Frontiers in Genomics Research, Volume One is available for Amazon.com Kindle

Newton, MA — (ReleaseWire) — 01/19/2016 — Leaders in Pharmaceutical Business Intelligence would like to announce the First volume of their BioMedical E-Book Series B: Series B: Frontiers in Genomics Research

Volume I: Genomics Orientations for Individualized Medicine which is now available on Amazon Kindle at

http://www.amazon.com/dp/B018DHBUO6

For more information visit:

http://www.sbwire.com/press-releases/leaders-in-pharmaceutical-business-intelligence-would-like-to-announce-first-volume-of-their-biomedical-e-book-series-b-on-genomics-available-on-amazon-kindle-657796.htm

Leaders in Pharmaceutical Business Intelligence (LPBI) Would Like to Announce Volume III of Their BioMedical E-Book Series E: Patient-Centered Medicine

LPBI Announces New e-Book available on Amazon! Volume Three: Milestones in Physiology & Discoveries in Medicine and Genomics

Newton, MA — (ReleaseWire) — 01/14/2016 — Leaders in Pharmaceutical Business Intelligence would like to announce Volume III of their BioMedical E-Book Series E: Patient-Centered Medicine

Volume Three: Milestones in Physiology & Discoveries in Medicine and Genomics which is now available on Amazon Kindle at

http://www.amazon.com/dp/B019VH97LU

For more information visit:

http://www.sbwire.com/press-releases/leaders-in-pharmaceutical-business-intelligence-would-like-to-announce-volume-iii-of-their-biomedical-e-book-series-e-patient-centered-medicine-657043.htm

Leaders in Pharmaceutical Business Intelligence (LPBI) Would Like to Announce the Second Volume of Their BioMedical E-Book Series A: E-Books on Cardiovascular Diseases

New e-Book Available on Amazon.com! Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation

Newton, MA — (ReleaseWire) — 01/15/2016 — Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation which is now available on Amazon Kindle at

http://www.amazon.com/dp/B018Q5MCN8

For more information visit:

http://www.sbwire.com/press-releases/leaders-in-pharmaceutical-business-intelligence-would-like-to-announce-the-second-volume-of-their-biomedical-e-book-series-a-e-books-on-cardiovascular-diseases-657023.htm

Leaders in Pharmaceutical Business Intelligence (LPBI) Would Like to Announce the Third Volume of Their BioMedical E-Book Series A: E-Books on Cardiovascular Diseases

LPBI Announces New e-Book available now on Amazon.com! Volume Three: Etiologies of Cardiovascular Diseases – Epigenetics, Genetics and Genomics

Newton, MA — (ReleaseWire) — 01/14/2016 — Leaders in Pharmaceutical Business Intelligence would like to announce the Third volume of their BioMedical E-Book Series A: e-Books on Cardiovascular Diseases.

Volume Three: Etiologies of Cardiovascular Diseases – Epigenetics, Genetics and Genomics which is now available on Amazon Kindle at

http://www.amazon.com/dp/B018PNHJ84

For more information visit:

http://www.sbwire.com/press-releases/leaders-in-pharmaceutical-business-intelligence-would-like-to-announce-the-third-volume-of-their-biomedical-e-book-series-a-e-books-on-cardiovascular-diseases-657034.htm

Leaders in Pharmaceutical Business Intelligence (LPBI) announces Amazon e-Book for Kindle Volume Four: Therapeutic Promise: Cardiovascular Diseases, Regenerative & Translational Medicine

LPBI Announces New e-Book available now on Amazon.com! Volume Four: Therapeutic Promise: Cardiovascular Diseases, Regenerative & Translational Medicine

Newton, MA — (ReleaseWire) — 01/15/2016 — Volume Four: Therapeutic Promise: Cardiovascular Diseases, Regenerative & Translational Medicine which is now available on Amazon Kindle at

http://www.amazon.com/dp/B019UM909A

For more information visit:

http://www.sbwire.com/press-releases/leaders-in-pharmaceutical-business-intelligence-would-like-to-announce-their-fourth-volume-of-their-biomedical-e-book-series-a-e-books-on-cardiovascular-diseases-657072.htm

All forthcoming BioMed e-Book Titles can be viewed at

http://pharmaceuticalintelligence.com/biomed-e-books/

Posted in Academic Publishing, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management | 1 Comment

One Response

on January 19, 2016 at 1:15 PM | Reply gerag2015

This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.

A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.

Loading...